Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Novartis
Mallinckrodt
McKinsey
Johnson and Johnson
Argus Health
Fuji
Express Scripts
Queensland Health
Teva

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,882,721

« Back to Dashboard

Which drugs does patent 8,882,721 protect, and when does it expire?

Patent 8,882,721 protects ADLYXIN and is included in one NDA.

This patent has twenty-four patent family members in twenty countries.
Summary for Patent: 8,882,721
Title:Drive assembly suitable for use in a drug delivery device and drug delivery device
Abstract: A drive assembly for use in a drug delivery device is proposed, the drive assembly comprising: a housing having a proximal end and a distal end; an axis extending between the proximal end and the distal end; at least one drive member; a piston rod adapted to be driven along the axis by the drive member; an indicator adapted to provide positional information about a position of the piston rod relative to the proximal end, wherein the indicator and the piston rod are configured to convert a movement of the piston rod with respect to the housing into a rotational movement of the indicator. Additionally, a drug delivery device comprising the drive assembly is provided for.
Inventor(s): Jones; Matthew Meredith (Warwick, GB), Plumptre; David Aubrey (Droitwich, GB)
Assignee: Sanofi-Aventis Deutschland GmbH (Frankfurt am Main, DE)
Application Number:12/991,471
Patent Claim Types:
see list of patent claims
Delivery; Device; Use;

Drugs Protected by US Patent 8,882,721

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sanofi-aventis Us ADLYXIN lixisenatide SOLUTION;SUBCUTANEOUS 208471-001 Jul 27, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Sanofi-aventis Us ADLYXIN lixisenatide SOLUTION;SUBCUTANEOUS 208471-002 Jul 27, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,882,721

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
08009260May 20, 2008
08011676Jun 27, 2008
PCT Information
PCT FiledMay 09, 2009PCT Application Number:PCT/EP2009/003310
PCT Publication Date:November 26, 2009PCT Publication Number: WO2009/141067

International Patents Family Members for US Patent 8,882,721

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Malaysia 150985 ➤ Subscribe
Mexico 2010012277 ➤ Subscribe
South Korea 101577944 ➤ Subscribe
South Korea 20110022607 ➤ Subscribe
Japan 5271411 ➤ Subscribe
Japan 2011520537 ➤ Subscribe
Israel 209364 ➤ Subscribe
Hungary E026467 ➤ Subscribe
Hong Kong 1153961 ➤ Subscribe
Spain 2553416 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
UBS
Covington
Fuji
Cantor Fitzgerald
Daiichi Sankyo
Moodys
Chubb
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot